Treatment of relapsed/refractory CLL with Venetoclax-Rituximab during the COVID-19 pandemic: A daily-life experience in southern Italy.
Main Article Content
Keywords
CLL, symptomatic COVID19 , Venetoclax-rituximab, time-limited therapy
Abstract
With more than 3 million proven infections and 100.000 associated deaths in Italy, the COVID-19 pandemic poses extraordinary challenges to health-care professionals and especially to those caring for patients with haematologic malignancies (1-2). Given the multiple immune defects characterizing chronic lymphocytic leukaemia (CLL), it is considered that patients with this form of leukemia have a high-risk of suffering severe forms of COVID-19 (3-4).
Downloads
Abstract 854
PDF Downloads 292
HTML Downloads 119
References
2. Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020 Oct;7(10):e737-e745.
3. Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood. 2015 Jul 30;126(5):573-581.
4. Langerbeins P, Eichhorst B. Immune Dysfunction in Patients with Chronic Lymphocytic Leukemia and Challenges during COVID-19 Pandemic. Acta Haematol . 2021 Feb 25;1-11. doi: 10.1159/000514071. Online ahead of print.
5. Koffman B, Mato A, Byrd JC, Danilov A, Hedrick B, Ujjani C,et al Management of CLL patients early in the COVID-19 pandemic: An international survey of CLL experts. Am J Hematol. 2020 Aug;95(8):E199-E203.
6. Baumann T, Delgado J, Montserrat E. CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report. Leukemia. 2020 Jul;34(7):1954-1956.
7. Thibaud S, Tremblay D, Bhalla S, Zimmerman B, Sigel K, Gabrilove J. Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19. Br J Haematol 2020 Jul;190(2):e73-e76.
8. Cuneo A, Scarfò L, Reda G, Varettoni M, Quaglia FM, Marchetti M, et al Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report. Blood. 2020 Aug 6;136(6):763-766.
9. Sehn LH, Kuruvilla P, Christofides A, Stakiw J. Management of chronic lymphocytic leukemia in Canada during the coronavirus pandemic. Curr Oncol. 2020 Jun;27(3):e332-e335.
10. Reda G, Noto A, Cassin R, Zamprogna G, Borella C, Scarfò L, et al. Reply to "CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report" Analysis of six hematological centers in Lombardy : On behalf of CLL commission of Lombardy Hematology Network (REL). Leukemia. 2020 Sep;34(9):2531-2532.
11. Rossi D, Shadman M, Condoluci A, Brown JR, Byrd JC, Gaidano G,et al How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic. Hemasphere. 2020 Jul 30;4(4):e432.
12. Montserrat E. When CLL meets COVID-19. Blood. 2020 Sep 3;136(10):1115-1116.
13. Scarfò L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C, et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia. 2020 Sep;34(9):2354-2363.
14. Mato AR, Roeker LE, Lamanna N, Allan JN, Leslie L, Pagel JM, et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020 Sep 3;136(10):1134-1143.
15. https://www.hematology.org/covid-19/covid-19-and-cll. COVID-19 and CLL: Frequently Asked Questions (Version 4.1; last updated February 2, 2021).
16. https://ehaweb.org/covid-19/covid-19-recommendations/recommendations-for-specific-hematologic-malignancies. COVID-19 and CLL: Frequently Asked Questions (Produced by the EHA SWG on CLL (ERIC) and endorsed by EHA).
17. Shadman M, Ujjani C. Vaccinations in CLL: implications for COVID-19. Blood
2021 14;137(2):144-146.
18. Roeker LE, Knorr DA, Pessin MS, Ramanathan LV, Thompson MC, Leslie LA, et al.
Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia. Leukemia 2020 Nov;34(11):3047-3049.
Article Sidebar
Article Details
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers. Authors will grant copyright of their articles to the Institute of Hematology, Catholic University, Rome . No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.